When Shipments Stop: Understanding And Managing Customs Delays In Clinical Supply Chains
By Joseph Weiford, global trade compliance professional
This article is part one of a five-part series exploring how clinical supply chains are affected by increasing complexity in global trade compliance. Across the series, we examine how delays emerge, why information that appears complete can still fall short at the point of review, and how a more structured approach to compliance can improve clarity, consistency, and decision-making.
Delays at the border are often treated as operational disruptions. In practice, they are more accurately understood as moments where compliance must be demonstrated under scrutiny.
For clinical supply chains, where timing and product integrity are critical, these events carry broader implications. Even brief delays can ripple through a clinical program, affecting dosing schedules, patient enrollment timelines, and data collection windows. For high-stakes therapies, the operational impact can be significant, making clarity in documentation and consistency in classification critical for trial success. A shipment delay is not simply a pause in transit. It is a point where documentation, classification, and admissibility are evaluated together, often under time pressure.
As clinical development models evolve, these moments are becoming more frequent.
Increasing Complexity In Clinical Supply Chains
Several trends are contributing to this shift. The continued growth of oncology pipelines, the expansion of adaptive and decentralized trial designs, and increased reliance on comparator sourcing across global markets have introduced greater variability into how products move and are documented.
Shipments now more frequently involve evolving product characteristics, multi-country sourcing and distribution, overlapping regulatory frameworks, and multiple stakeholders contributing to documentation. These factors do not inherently create compliance issues. They do, however, increase the likelihood that information will need to be interpreted across multiple contexts at the point of review.
Consider a shipment that originates in one country, is consolidated in another, and then distributed across multiple trial sites. Each step introduces potential differences in how product identity and handling requirements are documented, requiring careful alignment to ensure smooth border clearance.
These real-world scenarios illustrate that complexity is not just about volume but about variability in documentation, packaging, and regulatory interpretation across stakeholders.
What This Looks Like In Practice
These delays often arise in situations that are operationally routine but become more complex when the information supporting a shipment is considered together.
A clinical shipment may include an invoice describing the product at a high level, internal references tied to a protocol or compound identifier, and regulatory terminology aligned to submission pathways. Each description may be accurate within its own context. When considered together, however, the relationship between them may not be immediately clear. At that point, the issue is not the absence of information, but how those descriptions align. The shipment pauses while that alignment is clarified, often requiring coordination across internal and external teams to connect terminology that was never presented in a single unified form.
A similar dynamic can arise with temperature-controlled shipments. A shipment may include validated packaging, temperature monitoring data, and product classification and handling requirements, each supporting compliance from a different perspective. During review, the question becomes how these elements relate to one another. Where those relationships are not immediately apparent from the documentation provided, additional clarification may be required, extending release timelines even where the shipment was properly prepared.
Delays may also emerge when responses must be assembled across organizations. A request for information may require support from sponsors, manufacturers, and logistics providers, each holding a different part of the explanation. The delay is not necessarily driven by the complexity of the issue itself but by the time required to retrieve, align, and return a coherent response across multiple contributors and time zones.
Over the life of a clinical program, products may also evolve through packaging updates, labeling changes, or shifts in documentation format. Each shipment may be appropriate in isolation. However, where the relationship between earlier and later shipments is not clearly expressed, additional time may be required to understand how the product has evolved and how each movement relates to the next.
Even repeated shipments under the same program can introduce complexity. Descriptions may vary slightly, supporting detail may be presented differently, and rationale may not be expressed in the same way across entries. While each shipment may satisfy requirements individually, the variation becomes more visible over time and may require additional interpretation.
A Different Way To Understand Delays
These situations are not uncommon. They reflect how even well-prepared shipments can become difficult to interpret when information is not fully aligned across systems, stakeholders, and documentation.
From an operational standpoint, delays are often attributed to process or procedure. In practice, they frequently reflect how information is presented and how easily it can be understood in relation to itself at the point of review.
Looking Ahead
Understanding why this occurs requires looking more closely at how data, documentation, and decisions relate to one another across systems.
As clinical supply chains continue to grow in complexity, the challenge is not only ensuring that information is available but ensuring that it is aligned in a way that can be clearly interpreted when it matters most.
This shift — from information availability to information alignment — becomes central to how delays are experienced and resolved.
In the next article, we will explore why even complete information can fail at the point of review, and how visibility alone is not enough to prevent delays.
The views expressed are solely those of the author and do not represent the views of any government agency or organization.
About The Author:
Joseph Weiford is a global trade compliance professional with extensive experience in international supply chain risk, regulatory enforcement, and cross-border commerce. His work focuses on helping organizations navigate complex regulatory environments and maintain compliance while moving sensitive or high-value goods internationally. Drawing on experience with U.S. Customs and Border Protection and deep knowledge of global trade systems, he provides insight into the intersection of logistics, regulation, and operational risk. Joseph writes on trade compliance, supply chain transparency, and emerging technologies shaping global commerce, with a focus on protecting consumers and strengthening compliant international trade.